Integrated Filing — IndAS



General information about company
Scrip Code 544250
NSE Symbol SANOFICONR
MSEI Symbol NA
ISIN INE0UOS01011
Name of company SANOFI CONSUMER HEALTHCARE INDIA LIMITED
Type of company Main Board
Class of security Equity
Date of start of financial year 01-Jan-2025
Date of end of financial year 31-Dec-2025
Date of board meeting when results were approved 04-Aug-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 29-Jul-2025
Description of presentation currency INR (in Actuals)
Reporting Type Quarterly
Reporting Quarter Second quarter
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Unaudited
Segment Reporting Single segment
Description of single segment Pharma
Start date and time of board meeting 04-Aug-2025   14:30:00
End date and time of board meeting 04-Aug-2025   18:15:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Whether the company has any related party? Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. NA
Whether the company is a high value debt listed entity according to regulation 15 (1A)? No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company? Yes
Latest Date on which RPT policy is updated 2025-02-20
Indicate Company website link for updated RPT policy of the Company https://www.sanofi.com/assets/countries/india/docs/consumer-healthcare/investors/disclosures-under-reg-46-of-the-listing-regulations/code-of-conduct-and-policies/policy-on-related-party-transaction-india-2024.pdf
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? No
No. of times funds raised during the quarter
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? No
Please note that provisions of disclosure for the Default on Loans and Debt Securities is applicable to the Company. However, there are no such instances of default on loans and debt securities. Hence, we have selected No in this tab n n nNo loan or debt security



Financial Results Ind-AS
Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Apr-2025 01-Jan-2025
B Date of end of reporting period 30-Jun-2025 30-Jun-2025
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Standalone Standalone
Part I Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.
1 Income
Revenue from operations 2209000000 3935000000
Other income 56000000 108000000
Total income 2265000000 4043000000
2 Expenses
(a) Cost of materials consumed 554000000 743000000
(b) Purchases of stock-in-trade 46000000 381000000
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade 12000000 -124000000
(d) Employee benefit expense 320000000 616000000
(e) Finance costs 5000000 9000000
(f) Depreciation, depletion and amortisation expense 30000000 50000000
(f) Other Expenses
1 Other Expenses 575000000 977000000
Total other expenses 575000000 977000000
Total expenses 1542000000 2652000000
3 Total profit before exceptional items and tax 723000000 1391000000
4 Exceptional items 66000000 66000000
5 Total profit before tax 789000000 1457000000
6 Tax expense
7 Current tax 184000000 354000000
8 Deferred tax -2000000 -4000000
9 Total tax expenses 182000000 350000000
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0 0
11 Net Profit Loss for the period from continuing operations 607000000 1107000000
12 Profit (loss) from discontinued operations before tax 0 0
13 Tax expense of discontinued operations 0 0
14 Net profit (loss) from discontinued operation after tax 0 0
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0 0
16 Total profit (loss) for period 607000000 1107000000
17 Other comprehensive income net of taxes 0 0
18 Total Comprehensive Income for the period 607000000 1107000000
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 230000000 230000000
Face value of equity share capital 10 10
27 Details of debt securities
22 Reserves excluding revaluation reserve
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 26.36 48.07
Diluted earnings (loss) per share from continuing operations 26.36 48.07
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 26.36 48.07
Diluted earnings (loss) per share from continuing and discontinued operations 26.36 48.07
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results



Remarks
Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities
Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-Jan-2025
Date of end of reporting period 30-Jun-2025
Whether results are audited or unaudited Unaudited
Nature of report standalone or consolidated Standalone
Assets
1 Non-current assets
Property, plant and equipment 406000000
Capital work-in-progress 10000
Investment property 0
Goodwill 0
Other intangible assets 13000000
Intangible assets under development 0
Biological assets other than bearer plants 0
Investments accounted for using equity method 0
Non-current financial assets
Non-current investments 0
Trade receivables, non-current 0
Loans, non-current 0
Other non-current financial assets 37000000
Total non-current financial assets 37000000
Deferred tax assets (net) 66000000
Other non-current assets 37000000
Total non-current assets 559010000
2 Current assets
Inventories 780000000
Current financial asset
Current investments 0
Trade receivables, current 444000000
Cash and cash equivalents 2164000000
Bank balance other than cash and cash equivalents 5000000
Loans, current 1000000
Other current financial assets 11000000
Total current financial assets 2625000000
Current tax assets (net) 0
Other current assets 256000000
Total current assets 3661000000
3 Non-current assets classified as held for sale
4 Regulatory deferral account debit balances and related deferred tax Assets
Total assets 4220010000
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 230000000
Other equity 2340000000
Total equity attributable to owners of parent 2570000000
Non controlling interest
Total equity 2570000000
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 0
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises 0
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 0
Total Trade payable 0
Other non-current financial liabilities 210000000
Total non-current financial liabilities 210000000
Provisions, non-current 111000000
Deferred tax liabilities (net) 0
Deferred government grants, Non-current 0
Other non-current liabilities 0
Total non-current liabilities 321000000
Current liabilities
Current financial liabilities
Borrowings, current 0
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 23940000
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 907000000
Total Trade payable 930940000
Other current financial liabilities 78000000
Total current financial liabilities 1008940000
Other current liabilities 24000000
Provisions, current 296070000
Current tax liabilities (Net) 0
Deferred government grants, Current 0
Total current liabilities 1329010000
3 Liabilities directly associated with assets in disposal group classified as held for sale 0
4 Regulatory deferral account credit balances and related deferred tax liability 0
Total liabilities 1650010000
Total equity and liabilites 4220010000
Disclosure of notes on assets and liabilities



Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results
Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-Apr-2025 01-Jan-2025
Date of end of reporting period 30-Jun-2025 30-Jun-2025
Whether accounts are audited or unaudited Unaudited Unaudited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income
Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Apr-2025 01-Jan-2025
B Date of end of reporting period 30-Jun-2025 30-Jun-2025
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Standalone Standalone
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
Total Amount of items that will not be reclassified to profit and loss
2 Income tax relating to items that will not be reclassified to profit or loss
3 Amount of items that will be reclassified to profit and loss
Total Amount of items that will be reclassified to profit and loss
4 Income tax relating to items that will be reclassified to profit or loss
5 Total Other comprehensive income



Cash flow statement, indirect
Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-Jan-2025
B Date of end of reporting period 30-Jun-2025
C Whether results are audited or unaudited Unaudited
D Nature of report standalone or consolidated Standalone
Part I Blue color marked fields are non-mandatory.
Statement of cash flows
Cash flows from used in operating activities
Profit before tax 1457000000
Adjustments for reconcile profit (loss)
Adjustments for finance costs 9000000
Adjustments for decrease (increase) in inventories -371000000
Adjustments for decrease (increase) in trade receivables, current -289000000
Adjustments for decrease (increase) in trade receivables, non-current 0
Adjustments for decrease (increase) in other current assets -198000000
Adjustments for decrease (increase) in other non-current assets 0
Adjustments for other financial assets, non-current -1000000
Adjustments for other financial assets, current 31530000
Adjustments for other bank balances -4530000
Adjustments for increase (decrease) in trade payables, current 183000000
Adjustments for increase (decrease) in trade payables, non-current 0
Adjustments for increase (decrease) in other current liabilities -185000000
Adjustments for increase (decrease) in other non-current liabilities 0
Adjustments for depreciation and amortisation expense 50000000
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0
Adjustments for provisions, current -57000000
Adjustments for provisions, non-current 0
Adjustments for other financial liabilities, current 5000000
Adjustments for other financial liabilities, non-current 0
Adjustments for unrealised foreign exchange losses gains -21000000
Adjustments for dividend income 0
Adjustments for interest income 83000000
Adjustments for share-based payments 0
Adjustments for fair value losses (gains) 0
Adjustments for undistributed profits of associates 0
Other adjustments for which cash effects are investing or financing cash flow 0
Other adjustments to reconcile profit (loss) 0
Other adjustments for non-cash items 3000000
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0
Total adjustments for reconcile profit (loss) -928000000
Net cash flows from (used in) operations 529000000
Dividends received 0
Interest paid 0
Interest received 0
Income taxes paid (refund) 350000000
Other inflows (outflows) of cash 0
Net cash flows from (used in) operating activities 179000000
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0
Cash flows used in obtaining control of subsidiaries or other businesses 0
Other cash receipts from sales of equity or debt instruments of other entities 0
Other cash payments to acquire equity or debt instruments of other entities 0
Other cash receipts from sales of interests in joint ventures 0
Other cash payments to acquire interests in joint ventures 0
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0
Proceeds from sales of property, plant and equipment 0
Purchase of property, plant and equipment 69000000
Proceeds from sales of investment property 0
Purchase of investment property 0
Proceeds from sales of intangible assets 0
Purchase of intangible assets 0
Proceeds from sales of intangible assets under development 0
Purchase of intangible assets under development 0
Proceeds from sales of goodwill 0
Purchase of goodwill 0
Proceeds from biological assets other than bearer plants 0
Purchase of biological assets other than bearer plants 0
Proceeds from government grants 0
Proceeds from sales of other long-term assets 0
Purchase of other long-term assets 0
Cash advances and loans made to other parties 0
Cash receipts from repayment of advances and loans made to other parties 0
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0
Dividends received 0
Interest received 83000000
Income taxes paid (refund) 0
Other inflows (outflows) of cash 0
Net cash flows from (used in) investing activities 14000000
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0
Payments from changes in ownership interests in subsidiaries 0
Proceeds from issuing shares 0
Proceeds from issuing other equity instruments 0
Payments to acquire or redeem entity's shares 0
Payments of other equity instruments 0
Proceeds from exercise of stock options 0
Proceeds from issuing debentures notes bonds etc 0
Proceeds from borrowings 0
Repayments of borrowings 0
Payments of lease liabilities 31000000
Dividends paid 1267000000
Interest paid 0
Income taxes paid (refund) 0
Other inflows (outflows) of cash 0
Net cash flows from (used in) financing activities -1298000000
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes -1105000000
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 0
Net increase (decrease) in cash and cash equivalents -1105000000
Cash and cash equivalents cash flow statement at beginning of period 3269000000
Cash and cash equivalents cash flow statement at end of period 2164000000





Details of Impact of Audit Qualification
Whether results are audited or unaudited Unaudited
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Auditor's opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results Yes
Sr No. Audit firm's name Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI Certificate valid upto
1 Kalyaniwalla & Mistry LLP Yes 31-Jul-2027


Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)
Sr No. Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.
Details of the party (listed entity/subsidiary) entering into the transaction Details of the counterparty Type of related party transaction Details of other related party transaction Value of the related party transaction as approved by the audit committee Remarks on approval by audit committee Value of the related party transaction ratified by the audit committee Date of Audit Committee Meeting where the ratification was approved Value of transaction during the reporting period In case monies are due to either party as a result of the transaction In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments Details of the loans, inter-corporate deposits, advances or investments Notes
Name PAN Name PAN Relationship of the counterparty with the listed entity or its subsidiary Opening balance Closing balance Nature of indebtedness (loan/ issuance of debt/ any other etc.) Details of other indebtedness Cost Tenure Nature (loan/ advance/ intercorporate deposit/ investment ) Interest Rate (%) Tenure Secured/ unsecured Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
1 Sanofi Consumer Healthcare India Limited Opella Healthcare Group Common control Any other transaction Service charges received (Income) 30000000 Approved 0 0 0
2 Sanofi Consumer Healthcare India Limited Opella Healthcare Malaysia Common control Any other transaction Service charges received (Income) 10000000 Approved 0 0 0
3 Sanofi Consumer Healthcare India Limited Opella Healthcare International SAS Common control Purchase of goods or services 30000000 Approved 6700000 0 0
4 Sanofi Consumer Healthcare India Limited Opella Healthcare International SAS Common control Sale of goods or services 1100000000 Approved 620600000 0 0
5 Sanofi Consumer Healthcare India Limited Sanofi Healthcare India Private Limited Common control Any other transaction Payment against intangible asset 30000000 Approved 0 0 0
6 Sanofi Consumer Healthcare India Limited Sanofi India Limited Common control Purchase of goods or services 382000000 Approved 229530000 0 0
7 Sanofi Consumer Healthcare India Limited Sanofi India Limited Common control Any other transaction Expense for Consignment agency services 65000000 Approved 57030000 0 0
8 Sanofi Consumer Healthcare India Limited Sanofi India Limited Common control Any other transaction Expense recharge 50000000 Approved 31030000 0 0
9 Sanofi Consumer Healthcare India Limited Sanofi India Limited Common control Any other transaction HBSP commission 17000000 Approved 0 0 0
10 Sanofi Consumer Healthcare India Limited Sanofi India Limited Common control Any other transaction Inventory transfer (inward) 80000000 Approved 13430000 0 0
11 Sanofi Consumer Healthcare India Limited Sanofi India Limited Common control Any other transaction License fee (Income) 25000000 Approved 1100000 0 0
12 Sanofi Consumer Healthcare India Limited Sanofi India Limited Common control Any other transaction Rent (Expense) 1000000 Approved 170000 0 0
13 Sanofi Consumer Healthcare India Limited Opella Healthcare India Private Limited Common control Any other transaction Income from provision of Consignment agency services 232000000 Approved 47630000 0 0
14 Sanofi Consumer Healthcare India Limited Opella Healthcare India Private Limited Common control Any other transaction Service charges received (Income) 553000000 Approved 301650000 0 0
15 Sanofi Consumer Healthcare India Limited Opella Healthcare Participations B.V. Holding company Dividend paid 765000000 Approved 765030000 0 0
16 Sanofi Consumer Healthcare India Limited Himanshu Bakshi Key management personnel of entity or parent Remuneration Approved 33640000 0 0
17 Sanofi Consumer Healthcare India Limited Nikunj Savaliya Key management personnel of entity or parent Remuneration Approved 6260000 0 0
18 Sanofi Consumer Healthcare India Limited Maithilee Pathare Mistry Key management personnel of entity or parent Remuneration Approved 4040000 0 0
19 Sanofi Consumer Healthcare India Limited Amit Jain Key management personnel of entity or parent Remuneration Approved 600000 0 0
20 Sanofi Consumer Healthcare India Limited Shobinder Duggal Key management personnel of entity or parent Remuneration Approved 600000 0 0
21 Sanofi Consumer Healthcare India Limited Suparna Pandhi Key management personnel of entity or parent Remuneration Approved 750000 0 0
22 Sanofi Consumer Healthcare India Limited Opella Healthcare International SAS Common control Any other transaction Closing balance Approved 0 28000000 350860000
23 Sanofi Consumer Healthcare India Limited Sanofi India Limited Common control Any other transaction Closing balance Approved 0 63000000 520000
24 Sanofi Consumer Healthcare India Limited Sanofi India Limited Common control Any other transaction Closing balance Approved 0 288000000 30190000
25 Sanofi Consumer Healthcare India Limited Opella Healthcare International SAS Common control Any other transaction Closing balance Approved 0 0 6700000
26 Sanofi Consumer Healthcare India Limited Opella Healthcare India Private Limited Common control Any other transaction Closing balance Approved 0 35000000 12830000
Total value of transaction during the reporting period 2119790000